All In Biotech

Drug Trial Radar · NCT02556788

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,212

Actual

Start

Nov 2015

Primary completion

Feb 7, 2017

Study completion May 12, 2017

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Sep 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • CD5789 (trifarotene) 50µg/g CreamDrug

    CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.

  • Placebo CreamDrug

    Placebo cream applied once daily during 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)Time frame: From Baseline to Week 12

Locations

81 sites in 8 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site

    Birmingham, Alabama

  • Galderma Investigational Site

    Phoenix, Arizona

  • Galderma Investigational Site

    Tucson, Arizona

  • Galderma Investigational Site

    Fort Smith, Arkansas

  • Galderma Investigational Site

    Los Angeles, California

  • Galderma Investigational Site

    Murrieta, California

  • Galderma Investigational Site

    Santa Ana, California

  • Galderma Investigational Site

    Aventura, Florida

  • Galderma Investigational Site

    Miami, Florida

  • Galderma Investigational Site

    Miami Lakes, Florida

  • Galderma Investigational Site

    West Palm Beach, Florida

  • Galderma Investigational Site

    Corbin, Kentucky

  • Galderma Investigational Site

    Beverly, Massachusetts

  • Galderma Investigational Site

    Ann Arbor, Michigan

  • Galderma Investigational Site

    Detroit, Michigan

  • Galderma Investigational Site

    Brooklyn, New York

  • Galderma Investigational Site

    Stony Brook, New York

  • Galderma Investigational Site

    Wilmington, North Carolina

  • Galderma Investigational Site

    Fort Washington, Pennsylvania

  • Galderma Investigational Site

    Philadelphia, Pennsylvania

  • Galderma Investigational Site

    Greer, South Carolina

  • Galderma Investigational Site

    Goodlettsville, Tennessee

  • Galderma Invetsigational site

    Austin, Texas

  • Galderma Investigational Site

    Dallas, Texas

  • Galderma Investigational Site

    Houston, Texas

  • Galderma Investigational Site

    Pflugerville, Texas

  • Galderma Investigational Site

    San Antonio, Texas

  • Galderma Investigational Site

    Webster, Texas

  • Galderma Investigational Site

    Walla Walla, Washington

  • Galderma Investigational Site

    Chomutov, Czechia

  • Galderma Investigational Site

    Hradec Králové, Czechia

  • Galderma Investigational Site

    Kutná Hora, Czechia

  • Galderma Investigational Site

    Olomouc, Czechia

  • Galderma Investigational Site

    Pardubice, Czechia

  • Galderma Investigational Site

    Prague, Czechia

  • Galderma Investigational Site

    Prague, Czechia

  • Galderma Investigational Site

    Prague, Czechia

  • Galderma Investigational Site

    Budapest, Hungary

  • Galderma Investigational Site

    Budapest, Hungary

  • Galderma Investigational Site

    Debrecen, Hungary

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.